Bruker (NASDAQ:BRKR) Director Cynthia M. Friend Sells 3,535 Shares

Key Points

• Bruker Corporation Director Cynthia Friend sold 3,535 shares at an average price of $32.25, leading to a total transaction of $114,003.75 and a 16.40% decrease in ownership.
• The company's shares traded down 3.6% to $30.91, with a market capitalization of $4.69 billion and a PE ratio of 59.44.
• Bruker recently announced a quarterly dividend of $0.05 per share, representing a 0.6% dividend yield and scheduled for payment on October 3rd.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) Director Cynthia M. Friend sold 3,535 shares of the business's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Bruker Price Performance

BRKR traded down $1.15 during trading on Wednesday, hitting $32.11. 4,723,177 shares of the company traded hands, compared to its average volume of 4,441,078. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The company has a market cap of $4.87 billion, a PE ratio of 61.75, a P/E/G ratio of 4.62 and a beta of 1.21. The stock's 50-day simple moving average is $35.45 and its two-hundred day simple moving average is $38.64. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. During the same period last year, the company earned $0.52 EPS. The firm's revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, sell-side analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's dividend payout ratio is 38.46%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Barclays cut their target price on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Monday, August 4th. Bank of America dropped their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the company a "hold" rating in a research report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price target on Bruker and gave the stock a "buy" rating in a research report on Monday, August 4th. Finally, Wells Fargo & Company cut their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $51.30.

Institutional Investors Weigh In On Bruker

A number of institutional investors and hedge funds have recently bought and sold shares of BRKR. Nisa Investment Advisors LLC grew its holdings in Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock worth $25,000 after acquiring an additional 487 shares in the last quarter. Pinnacle Bancorp Inc. bought a new position in shares of Bruker during the first quarter valued at approximately $29,000. Allworth Financial LP increased its holdings in Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after buying an additional 364 shares during the period. Huntington National Bank raised its stake in Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock worth $30,000 after buying an additional 645 shares in the last quarter. Finally, Spire Wealth Management purchased a new stake in Bruker during the second quarter worth $32,000. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.